Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics ' ( VKTX 0.32%) stock in ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

Baron Fifth Avenue Growth Fund declined during the first quarter of 2025, underperforming its benchmark, the Russell 1000 ...

Donald Trump has embarked on a tax-cutting and deregulation drive - Anna Moneymaker/) Donald Trump’s sweeping tax cuts risk ...

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound. The importance of biosimilars only continues to grow ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after confirming he was under investigation last week. AZ also said four other ...